Page last updated: 2024-12-08

cellulose triacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cellulose triacetate: for hemodialysis filtration [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID230396
SCHEMBL ID14342137
MeSH IDM0083141

Synonyms (14)

Synonym
31873-40-2
nsc25293
nsc-25293
2,3,4,6-tetra-o-acetylhexopyranosyl-(1->4)-2,3,6-tri-o-acetylhexopyranosyl-(1->4)-1,2,3,6-tetra-o-acetylhexopyranose
FT-0664457
cellulose triacetate
9012-09-3
17690-94-7
355012-91-8
d-(+)-cellohexose eicosaacetate
SCHEMBL14342137
DTXSID60282264
FT-0670929
FT-0664454

Research Excerpts

Overview

Cellulose triacetate appears to be a good alternative for these patients. Cellulose Triacetate is a plastic material manufactured from cellulose.

ExcerptReferenceRelevance
"Cellulose triacetate appears to be a good alternative for these patients."( Incidence of Hypersensitivity Reactions During Hemodialysis.
Alexandru, S; Astudillo, E; Carreño, G; Cidraque, I; Cintra, M; Esteras, R; Fernández-Prado, R; González-Parra, E; Ledesma, G; Martín-Navarro, J; Mas, S; Milla, M; Ortiz, A; Sánchez, E; Sánchez, R; Sanz, I; Tarragón, B; Tejeiro, RD, 2018
)
1.2
"Cellulose triacetate is a plastic material manufactured from cellulose."( Cellulose triacetate as a high-performance membrane.
Masuda, T; Sunohara, T, 2011
)
2.53

Effects

cellulose triacetate membrane has greater performance because of the lower thickness of the membrane and its lack of swelling due to high hydrophobicity.

ExcerptReferenceRelevance
"The cellulose triacetate membrane has a homogeneous membrane structure."( Cellulose triacetate as a high-performance membrane.
Masuda, T; Sunohara, T, 2011
)
2.29
"The cellulose triacetate membrane has greater performance because of the lower thickness of the membrane and its lack of swelling due to high hydrophobicity."( The past, present and future of the dialyzer.
Mineshima, M, 2015
)
0.9
"The cellulose triacetate membrane has a homogeneous membrane structure."( Cellulose triacetate as a high-performance membrane.
Masuda, T; Sunohara, T, 2011
)
2.29

Treatment

ExcerptReferenceRelevance
"The treatment of cellulose triacetate membranes reduced both the initial flux and the extent of water fouling."( Phospholipid coatings for the prevention of membrane fouling.
Dudley, LY; Hawes, C; Morgan, NL; Perl, O; Reuben, BG; Stratford, P, 1995
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The serum concentrations were used to calculate all relevant pharmacokinetic parameters."( Clearance of vancomycin during high-efficiency hemodialysis.
Kasiwong, S; Klansuwan, N; Ratanajamit, C; Wangsiripaisan, A, 2006
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
"A new artificial liver support system (ALSS) consisting of plasma exchange (PE) in combination with hemodiafiltration (HDF) using high-performance membranes of polymethyl methacrylate (PMMA) and cellulose triacetate (CTA) was developed to efficiently remove middle molecules from plasma and treat fulminant hepatic failure (FHF) complicated by the onset of hepatic coma."( Development of reliable artificial liver support (ALS)--plasma exchange in combination with hemodiafiltration using high-performance membranes.
Iwamura, Y; Sekiyama, K; Sugata, F; Yoshiba, M, 1993
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The determination of vancomycin removal can be used to estimate vancomycin serum concentrations as well as dosage requirements."( Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.
Dombrouski, J; Hoffman, EJ; Mason, NA; Odeh, RM; Patel, JA; Swartz, RD; Welage, LS, 1995
)
0.66
" An understanding of vancomycin's predominant dialytic mass transfer mechanism under a given set of operating conditions, including dialyser type and flow rates, may permit more accurate dosing of the drug."( Vancomycin mass transfer characteristics of high-flux cellulosic dialysers.
Clark, WR; Mueller, BA; Scott, MK, 1997
)
0.3
"The presence of carboxyhemoglobin in non-smokers exposed to methylene chloride results primarily from the metabolism of methylene chloride in the liver and exhibits a linear dose-response relationship."( Observed versus predicted carboxyhemoglobin levels in cellulose triacetate workers exposed to methylene chloride.
Amsel, J; Sielken, RL; Soden, KJ; Valdez-Flora, C, 2001
)
0.56
" Vancomycin 15 mg/kg over the last hour of dialysis resulted in significantly lower subsequent predialysis concentrations than the other dosing schemes."( Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
Mason, NA; Neudeck, BL; Patel, JA; Swartz, RD; Welage, LS, 2003
)
0.55
"Vancomycin administration of 30 mg/kg over the last 2 hours of dialysis achieves serum concentrations similar to conventional dosing of 15 mg/kg after dialysis and would allow dosing on a weekly basis."( Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
Mason, NA; Neudeck, BL; Patel, JA; Swartz, RD; Welage, LS, 2003
)
0.55
"Predict the appropriate vancomycin intradialytic dosage and dosing interval among patients receiving HEHD."( Clearance of vancomycin during high-efficiency hemodialysis.
Kasiwong, S; Klansuwan, N; Ratanajamit, C; Wangsiripaisan, A, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (169)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (6.51)18.7374
1990's43 (25.44)18.2507
2000's36 (21.30)29.6817
2010's70 (41.42)24.3611
2020's9 (5.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.24 (24.57)
Research Supply Index5.34 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index72.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (10.11%)5.53%
Reviews4 (2.13%)6.00%
Case Studies4 (2.13%)4.05%
Observational2 (1.06%)0.25%
Other159 (84.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]